Jun 25, 2019 / 07:20PM GMT
George Farmer - BMO Capital Markets Equity Research - Analyst
Good afternoon, everyone. My name is George Farmer. I'm a biotechnology analyst here at BMO. It's my pleasure to have Pam Cohen here with us here from Moderna. She's the head of Oncology Clinical Development at the company. And she's going to talk to us about Moderna's platform and its application in oncology indication specifically, and how Moderna is using messenger RNA-based vaccines for treating cancer.
Questions and Answers:
George Farmer - BMO Capital Markets Equity Research - AnalystSo Pam, why don't we start off, perhaps you could just walk us through the approach that Moderna is using involving messenger RNA-based vaccine?
Pamela S. Cohen - Moderna, Inc. - Head of Clinical Oncology Development
Sure. And thank you for having me, George. So we know that mutation-derived epitopes are important to activate T cells in patients with cancer and they drive, to some extent, the antitumor response that is seen with checkpoint inhibitors, and that's
Trustpilot
